Atopic Dermatitis Breakfast Briefing from #AADVMX2021 – DAY 2
April 24, 2021
Durability of Response to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis (AD) After Treatment Discontinuation in a Phase 2b Trial
Melinda J. Gooderham, Giampiero Girolomoni, Julian O. Moore, Jonathan I. Silverberg, Robert Bissonnette, Seth Forman, Elena Peeva, Pinaki Biswas, Hernan Valdez, and Gary Chan
Atopic Dermatitis Breakfast Briefing from #AADVMX2021 – Day 1
April 23, 2021
Depth of Response to Abrocitinib in Adults With Moderate-to-Severe Atopic Dermatitis (AD): Pooled Analysis of Monotherapy Studies
Sonja Ständer, Neal Bhatia, Melinda J. Gooderham, Jonathan I. Silverberg, Jacob P. Thyssen, Pinaki Biswas, Marco DiBonaventura, William Romero, and Saleem A. Farooqui